These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25858607)

  • 21. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
    Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
    Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
    Blanco JL; Rojas J; Paredes R; Negredo E; Mallolas J; Casadella M; Clotet B; Gatell JM; de Lazzari E; Martinez E;
    J Antimicrob Chemother; 2018 Jul; 73(7):1965-1971. PubMed ID: 29608685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
    Quercia R; Roberts J; Martin-Carpenter L; Zala C
    Clin Drug Investig; 2015 Mar; 35(3):211-9. PubMed ID: 25637061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
    Pialoux G; Marcelin AG; Cawston H; Guilmet C; Finkielsztejn L; Laurisse A; Aubin C
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):83-91. PubMed ID: 28741965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.
    Fida M; Rizza SA; Temesgen Z
    Drugs Today (Barc); 2019 May; 55(5):297-304. PubMed ID: 31131840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection.
    Osterholzer DA; Goldman M
    Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients.
    Zhang J; Hayes S; Sadler BM; Minto I; Brandt J; Piscitelli S; Min S; Song IH
    Br J Clin Pharmacol; 2015 Sep; 80(3):502-14. PubMed ID: 25819132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dolutegravir: an exciting new kid on the block.
    Blanco Arévalo JL; Whitlock GG
    Expert Opin Pharmacother; 2014 Mar; 15(4):573-82. PubMed ID: 24446762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
    Akil B; Blick G; Hagins DP; Ramgopal MN; Richmond GJ; Samuel RM; Givens N; Vavro C; Song IH; Wynne B; Ait-Khaled M;
    Antivir Ther; 2015; 20(3):343-8. PubMed ID: 25321146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference.
    Gervasoni C; Riva A; Cozzi V; Capetti A; Rizzardini G; Clementi E; Cattaneo D
    J Antimicrob Chemother; 2017 Jun; 72(6):1842-1844. PubMed ID: 28333266
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mechanisms of action, pharmacology and interactions of dolutegravir].
    Ribera E; Podzamczer D
    Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():2-8. PubMed ID: 25858605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV.
    Kandel CE; Walmsley SL
    Drug Des Devel Ther; 2015; 9():3547-55. PubMed ID: 26185421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of dolutegravir and rilpivirine, enhanced by foscarnet induction, in effective salvage antiretroviral therapy.
    Leporrier J; Etienne M; Chapuzet C; Peytavin G; Bord S; Borsa-Lebas F; Caron F; Plantier JC; Mourez T
    J Clin Virol; 2014 Aug; 60(4):428-30. PubMed ID: 24932736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
    Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.